UChicago Medicine	Medical Laboratories	I	Exome Requisition Form	
Client Account	ccount not set up,	5841 Sou Toll Fr	rsity of Chicago Genetic Services Laboratori outh Maryland Avenue, Room G701/MC0077, Chicago, IL 60637 Free: 888.824.3637 Local: 773.834.0555 Fax: 773.702.9130 cago.edu dnatesting.uchicago.edu CLIA#: 14D0671659 CAP#: 18	
Sex assigned at birth:	lale Female African/African-Ame	MRN: erican	Date of Birth:anAshkenazi JewishOther rements: 3-10cc blood in an EDTA (purple top) tube. DNA samples are only accepted a our website for other specimen requirements.	
Ordering Physicia:	Fax:		Email:	
In addition, the following mus and brain imaging reports. Parental Samples MOTHER Date Sample Drawn Name: Last	Parental samples are reco	samples for exome sec ommended. Send 3-10ccc in El Not A First ptomatic Symptoma	Date of Birth: atic (attach summary offindings) ot AvailableTo be sent later	
MRN: Test Requested (REQU Exome Sequencing Exome Sequencing	Asym IRED) (Proband only) (Trio) [parent sat	ptomatic Symptoma	atic (attach summary offindings) STAT Exome Sequencing (Proband only)* STAT Exome Sequencing (Trio) [parent samples required]* o ordering STAT exome testing.	
Ordering Checklist Test Requisition Form (require Completed Indication for Tes Completed Clinical Checklist Completed Billing Information Completed Exome Consent F Completed Research Consert Note: All samples should be shipped via overnigt page. No weekend or holiday deliveries. Label ee sample collected.	ed) ting/ICD-10 study coo (required) n (required) Form (required)	de (required)	For Office Use Only	



CLINICAL CHECKLIST - Requisition Form REQUIRED

Please check all clinical features that apply, and use the additional space provided at the bottom of the form if needed

erinatal History	Brain (Structural Anomalies) - please also provide MRI / imaging reports	Cutaneous
	YES (see below) NO UNKNOWN	YES (see below) NO UNKNOWN please specify:
Abnormal prenatal development -	Agenesis of corpus callosum	please specify.
please specify:		
	Cortical dysplasia	Cardiac
ognitive / Developmental	Cerebellar hypoplasia	YES (see below) NO UNKNOWN
YES (see below)	Dandy-Walker malformation	
Cognitive impairment (please provide	Heterotopia	Heart malformation – please specify:
details):	Hydrocephalus	
Developmental regression	Lissencephaly	Other:
Global developmental delay	Polymicrogyria	
Mild Moderate Severe	Pachygyria	Hematologic/Immunologic
Motor delay	Other:	YES (see below) NO UNKNOWN
Speech delay	Craniofacial	
	YES (see below) NO UNKNOWN	Anemia/neutropenia/pancytopenia
ehavioral	Cleft lip and/or palate	Other:
YES (see below)		Musculoskeletal
Autism spectrum disorder	-	YES (see below) NO UNKNOWN
Behavioral / Psychiatric abnormality -	Dysmorphic facies Specify:	Congenital diaphragmatic hernia
please specify:	Macrocephaly, HC:	Digital abnormality – please specify:
eurological		(Poly / Oligo / Other:)
YES (see below) NO UNKNOWN	Microcephaly, HC:	Limb abnormality – please specify:
	Hearing/Vision	
Movement abnormality – please specify:	YES (see below) NO UNKNOWN	Limb joint contracture(s)
	Vision abnormality – please specify	
		Other:
Dystonia	Hearing impairment – please specify	
Chorea		Genitourinary
Other	Other:	
Encephalopathy		Genital system abnormality - please
Hypertonia	Growth	specify:
Hypotonia (muscular)		Kidney abnormality - please specify:
Spina bifida	Failure to thrive	Other:
Additional findings:	Overgrowth	
	Short stature	
	Hemihypertrophy	Family History
	Other:	YES (see below) NO UNKNOWN
	Gastrointestinal (GI)	Parents with 2 or more miscarriages
	YES (see below) NO UNKNOWN	Other relatives with similar clinical histor
	please specify:	(please include detailed pedigree)
Ple	ease include any additional relevant clinical informatio	n here:
In addition to this checklist, the following mus	st also be sent with samples for exome sequencir	ng: detailed clinic notes, pedigree, results of prio

-2-

UChicago Medical	Ы	LLING OPTI	UNS
Medicine	Samples received with ir	ncomplete billing information	on will delay processing time.
Client Account Code:	Test canceled while "in progress'	will be billed for the amou	int of work completed up to that point.
Client Account Code:	For client account or institutional billing qu For insurance	iestions: venessa.gamboa or patient billing questions	
Patient Name: Last	First	(MI):	Date of Birth:
1.) Institutional Billing Billing Institution and Client A	ccount Code		_PO#:
Financial Contact:		Phone:	Fax:
	City		State:Zip:
Address:	Oity		
Email (required):	EASE NOTE: We do NOT accept Illinois	or any out-of-state Mec	
Email (required): 2.) Insurance Billing PL and back of the insurance of Medicare patients. Please contact ICD-10 Diagnosis Code(s):		or any out-of-state Mec UST BE INCLUDED . A c ent billing questions. (Must be	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f
Email (required): 2.) Insurance Billing PL and back of the insurance of Medicare patients. Please contact ICD-10 Diagnosis Code(s): Policyholder Name:	EASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Mec IUST BE INCLUDED. A c ent billing questions. (Must be Date of Birth:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal
Email (required):	EASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Mec IUST BE INCLUDED. A c ent billing questions. (Must be Date of Birth: City:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal State:Zip:
Email (required): 2.) Insurance Billing PL and back of the insurance of Medicare patients. Please contact ICD-10 Diagnosis Code(s): Policyholder Name: Policyholder Address: Relationship to the Patient:	EASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Med UST BE INCLUDED . A d ent billing questions. (Must be Date of Birth: City: Other Preauthorization	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal State:Zip: #(required):
Email (required):	ASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Med UST BE INCLUDED. A d ent billing questions. (Must be Date of Birth: City: Other Preauthorization Policy No.	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal State:Zip: # (required): Group No.:
Email (required):	ASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Med IUST BE INCLUDED. A d ent billing questions. (Must be Date of Birth: City: Dther Preauthorization Policy No City:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex: MaleFemal State:Zip: Group No.: State:Zip:
Email (required): 2.) Insurance Billing PL and back of the insurance of Medicare patients. Please contact ICD-10 Diagnosis Code(s): Policyholder Name: Policyholder Address: Relationship to the Patient: [Name of Primary Insurance:_ Insurance Address: PCP/Referring Physician Na	ASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Med IUST BE INCLUDED. A d ent billing questions. (Must be Date of Birth: City: Policy No City:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal State:Zip: Group No.: State:Zip:
Email (required):	EASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati	or any out-of-state Med IUST BE INCLUDED. A d ent billing questions. (Must be Date of Birth: City: Policy No City:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex:MaleFemal State:Zip: # (required): Group No.: State:Zip:
Email (required):	ASE NOTE: We do NOT accept Illinois ard and insurance prior authorization M t us at 1-844-843-3594 for insurance or pati Self Spouse Dependent C me:	or any out-of-state Mec UST BE INCLUDED. A c ent billing questions. (Must be Date of Birth: City: Policy No City: City: City: City: City: City: City: City: City: City: City: City: City: City: City: City: City:	dicaid. A legible photocopy of the f completed and signed ABN is REQUIRED provided or insurance cannot be f Sex: MaleFemal State:Zip: # (required): Group No.: State:Zip: State:Zip: State:Zip: State:Zip:

See our QuickGuide to Genetic Testing for complete list of Tests, TAT and CPT Codes.



EXOME CONSENT FORM – The University of Chicago The Division of Biological Sciences | University of Chicago Medical Center REQUIRED

Patient Name : _____

Date of Birth:

Overview

The UCGS Exome Sequencing Test attempts to evaluate the proteincoding regions of the human genome, which represents approximately 20,000 genes. These regions of DNA are referred to as 'exome'. The exome accounts for approximately 2% of the genome and comprises the majority of DNA variations that cause human disease. Exome sequencing is a useful and powerful tool for diagnostic applications and has been utilized to identify mutations in disorders that are both genetically and phenotypically heterogeneous and to identify mutations in genes associated with Mendelian disorders. The purpose of this test is to identify the underlying molecular basis of the disorder in this patient's family.

Accuracy

The studies performed are specific to the clinical features/suspected diagnosis indicated.

Accurate interpretation of test results may require an accurate report of the patient's family medical history, and that the reported family relationships are the true biological relationships.

There is always a small possibility of an error or failure in sample analysis; this is always a possibility with complex testing in any laboratory. Extensive measures are taken to avoid these errors.

The accuracy of genetic testing is limited by the methods employed, and sometimes by the nature of the condition for which testing is requested.

Limitations

Not all the exons in the genome are targeted and captured due to certain inherent characteristics of the genome. Approximately 90-95% of exons are targeted at a minimum depth of 30X in the diagnostic exome test. In addition, there is limited or no coverage in regions outside of the exome.

Certain types of mutations are not detectable by this test. This methodology will not detect low level mosaicism, copy number variation (i.e such as the deletion or duplication of an exon) and trinucleotide repeat expansions. Other types of rare genetic variation can interfere with this analysis.

Pathogenic variants may be present in a region of a gene not covered by this test. Absence of findings for any particular gene does not mean that there are no pathogenic variants present in that gene.

It is the responsibility of the referring physician, or a health care professional designated by the physician, to understand the limitations of the testing ordered, and to educate the patient regarding these limitations.

Testing & Analysis Pipeline

Of the thousands of variants identified by exome sequencing, a list of variants in genes that could potentially be related to the phenotype in the patient is generated. Most variants identified will NOT undergo interpretation by a laboratory member. Only those variants identified as potentially relevant to the patient's condition are reviewed by a team of Board-Certified PhD geneticists, MD geneticists, and genetic counselors who will determine the likelihood of the variant being related to the disorder.

Parental Analysis

Biological parental samples are requested in order to facilitate the interpretation of results. Exome sequencing will be performed on parental samples. A separate parental report will not be issued.

Genetic studies of families can sometimes reveal that the true biological relationships are not consistent with the relationships reported in the family history (such as in cases of adoption or non-paternity). It is this laboratory's policy NOT to report these findings, except in rare circumstances in which the findings indicate a medical or reproductive risk for which intervention is possible. These decisions will be made by the laboratory directors in consultation with medical, counseling and legal professionals as well as medical professionals trained in ethics (moral questions) who will determine the most appropriate means of conveying the information.

What is Reported?

UCGS will report on genetic variants that have been reported to be pathogenic, predicted to be pathogenic, possibly pathogenic as well as unclassified variants in established genes for the clinical features/suspected condition indicated for the patient. In addition, truncating pathogenic variants and variants that have been previously reported to be pathogenic or possibly pathogenic in genes hypothesized to be related to the cause of the patient's phenotype will also be reported.

What is Not Reported?

- Benign sequence changes not associated with disease and are commonly identified in healthy people.
- Synonymous (silent) sequence changes not associated with a change in the amino acid sequence.
- Variations associated with increased or decreased risk to develop common disorders (like high blood pressure) or involved in drug metabolism. Variations that have been associated with an increased risk for diseases that might present at an advanced age (like Alzheimer's Disease) in which there is no treatment or preventative measures.
- Heterozygous unclassified variants associated with a recessive disorder unless a deleterious mutation or a second unclassified variant in the same gene is also detected.
- Pathogenic mutations and variants in genes with no current known association with disease.



EXOME CONSENT FORM – The University of Chicago The Division of Biological Sciences | University of Chicago Medical Center REQUIRED

Carrier Status of Recessive Disorders for Reproductive Screening

Every individual is a carrier of anywhere from 0 to 10 mutations in genes known to cause significant human disease. Carriers are typically unaffected, but are at risk of transmitting these mutations to their future offspring. Recurrence risk for carrier parents of the same human disease is 25%. The UCGS Exome is not meant to be utilized as a comprehensive carrier test as an individual may be a carrier of type of mutation not screened for by this test or may be a carrier of a condition in which there was little or no coverage for. UCGS will report pathogenic variants in the following conditions: Bloom syndrome, Canavan disease, Cystic Fibrosis, Familial Dysautonomia, Fanconi Anemia type C, Gaucher disease type 1, Hb Beta Chain Related Hemoglobinopathy (Beta Thalassemia & Sickle Cell Disease, Tay Sachs disease, Mucolipidosis IV, Niemann Pick Type A

Please read the below statement carefully and initial the appropriate box. If neither box is checked, the lab will default to the YES/reporting option.

Initial

YES, please report carrier status. By checking this box, I choose to receive information regarding carrier status

NO, please do NOT report carrier status. By checking this box, I choose NOT to receive information regarding carrier status

Secondary Findings

The American College of Medical Genetics and Genomics (ACMG) recommends a minimal list of secondary findings to report from clinical sequencing. All of the included disorders are rare and were selected because preventive measures and/or treatments are available. Many individuals with pathogenic variants in these conditions might be asymptomatic for long periods of time. UCGS will report pathogenic variants in these genes as recommended by the ACMG. For further information please refer to the "ACMG SF v3.1 List for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing: a Policy Statement of the American College of Medical Genetics and Genomics (ACMG)"

Request to Opt-out of Receiving Secondary Findings as Recommended by ACMG

UCGS is giving patients the option of opting out of receiving the above secondary findings recommended by ACMG.

Please read the below statements carefully. <u>Only sign and date the</u> below if you wish to opt out of receiving unrelated secondary findings as recommended by ACMG

I choose <u>NOT</u> to receive information about secondary findings in the genes recommended by ACMG.

Patient or Legally Authorized Representative:

Date:

If Legally Authorized Representative please describe relationship to individual:

Implication of Results

Because the implications of genetic testing results can be complex, involving both medical and emotional and social issues, results will only be reported through the referring physician or a professional designated by the physician, such as a genetic counselor. The issues associated with some types of genetic testing are particularly sensitive. Therefore, the laboratory reserves the right to provide testing only if genetic counseling can be provided.

Confidentiality

Results and patient information are confidential and will only be released to the referring physician, unless written consent for further distribution is provided or the laboratory directors are required by law to release this information. For patients within The University of Chicago affiliated centers, policy may require that reports are provided to the medical records department.

Consent For Exome Sequencing

Signature of Parent/Guardian/ Legally Authorized Representative:

Date: _____

If Legally Authorized Representative please describe relationship to individual:

Referring Clinician

By signing this consent form, the referring clinician 1) indicates that this consent form has been reviewed with the patient and/or the patient's parent or guardian, and 2) accepts responsibility for pre- and post- test genetic counseling.

Signature of Referring Clinician:

Date: _____



RESEARCH CONSENT FORM – The University of Chicago The Division of Biological Sciences | University of Chicago Medical Center

CONSENT/AUTHORIZATION BY SUBJECT FOR PARTICIPATION IN A RESEARCH PROTOCOL FOR THE BETTER UNDERSTANDING OF THEIR GENETIC CONDITION

Protocol Number: 11-0151

Name of Subject :

Date of Birth:

STUDY TITLE: Molecular Genetic Studies of Rare Orphan Genetic Disease

Research Team: Soma Das, Ph.D.

5841 S. Maryland Ave. Room L-155 MC 0077, Chicago, IL 60637 773-834-0555

You are being asked to participate/allow your child to participate in a research study that may help us learn more about the genetic condition for which you/your child are being tested. This consent form describes the study, the risks and benefits of participation, as well as how your confidentiality will be maintained. Please take your time to contact us with questions and feel comfortable making a decision whether to participate or not. If you decide to participate in this study, please sign this form. Throughout this consent form, "you" will refer to you or your child, as appropriate.

WHY IS THIS STUDY BEING DONE?

You have already consented to clinical genetic testing. We are asking you to also participate in further studies. The purpose of these studies is to learn more about the genetic cause of diseases tested for in our lab, gather more information about these disorders, and experiment with new methods that may be better for testing.

WHAT IS INVOLVED IN THE STUDY?

During this study, Dr. Das and her team will collect information about you for this research. We may contact your doctor to request additional Protected Health Information (PHI), which consists of any health information related to your diagnosis (such as date of birth, medical record number, primary diagnosis, clinical features, relevant and family history, outcome). The data collected will be used to develop a database of patients being tested for genetic diseases and will be kept for the duration of the database. This study will look at how often different genetic mutations happen and clinical information related to the mutation.

When our lab is researching new genes or testing methods that are related to your diagnosis, we may include your sample, with others from similar patients in a small study before offering this new test. This data will help in directing doctors about the likelihood of a positive or negative test result in their patient. We may also use your sample to set up new methods that will improve the clinical testing in our laboratory. Your clinical information and sample, without any identifiers, may also be shared with other researchers that are interested in this specific condition.

HOW LONG WILL I BE IN THE STUDY?

Once enrolled, you will likely remain in this study as long as your DNA sample remains in our laboratory. If you want your sample, to be removed from the study at any time, please contact us, and the sample will not be used for further studies. Existing results will remain in our database until the study ends. For minors (those less than 18 years of age), their sample/data will be deleted or de-identified once they reach the age of majority (18 years or older) unless they are re - consented. Three attempts will be made at attempting re-consent before sample/data is deleted or de-identified. Sample/data will not be used in the study during the time period of trying to contact individuals for re - consenting purposes.

WHAT ARE THE RISKS OF THE STUDY?

There are no known added risks of the research. No additional information will be obtained from you, as all of the information has already been collected as part of clinical genetic testing or evaluation by your doctor.

ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? If

you agree to take part in this study, there may be direct medical benefit to your family. We may identify a cause for the genetic disease in your family. If a mutation is identified in your DNA, through our testing, your referring doctor will be notified and will receive a clinical report. Our study may also be helpful in finding the genetic causes of disease and will benefit doctors and patients as a group.

WHAT OTHER OPTIONS ARE THERE? You may choose not to participate.

WHAT ARE THE COSTS?

There will be no additional costs to you or your insurance company resulting from this research study. However, you or your insurance company will be responsible for costs related to your usual medical care.

WILL I BE PAID FOR MY PARTICIPATION?

You and your child will not be paid to participate.

WHAT ABOUT PRIVACY?

Study records that identify you will be kept private. All of your personal information will be entered into a password-protected database to prevent access to non-authorized personnel. If your data is shared with other researchers, all patient identifiers will be removed. Data from this study may be used in medical journals or presentations. If results from this study or related studies are made public in a medical journal, individual patients will not be identified. If we wish to use a patient's identity in a medical journal, we will ask for your permission at that time.

As part of the study, Dr. Das and her team will report any positive results of further testing to your referring doctor and/or genetic counselor. Dr. Das may also share these results, without your name or date of birth, with other researchers.



RESEARCH CONSENT FORM – The University of Chicago The Division of Biological Sciences | University of Chicago Medical Center

People from the University of Chicago, including the Institutional Review Board (IRB), a committee that oversees research at the University of Chicago, may also view the records of the research. If health information is shared outside the University of Chicago, the same laws that the University of Chicago must obey may not protect your health information. Dr. Das does not have to give you any results that are not are not important to your health or your family's health at that time.

This consent form will be kept by the research team for at least six years. The study results will be kept in your child's research record and be used by the research team indefinitely. When the study ends, your personal information will be removed from all results. Any information shared with your doctor may be included in your medical record and kept forever.

The Genetic Information Nondiscrimination Act (GINA) is a federal law that may help protect you from health insurance or employment discrimination based on genetic information. GINA is a federal law that will protect you in the following ways:

- Health insurance companies and group plans may not request genetic information from this research;
- Health insurance companies and group plans may not use your genetic information when making decisions regarding your eligibility or premiums;
- Employers with 15 or more employees may not use your genetic information when making a decision to hire, promote, or fire you or when setting the terms of your employment.

GINA does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance. GINA also does not protect you against discrimination based on an already-diagnosed genetic condition or disease.

WHAT ARE MY RIGHTS AS A PARTICIPANT?

Taking part in this study is optional. You may choose not to participate at any time during the study. Choosing not to participate or leaving the study will not affect your child's testing at the University of Chicago.

If you choose to leave the study and you do not want any of your child's future health information to be used, you must inform Dr. Das in writing at the address on the first page. Dr. Das may still use your child's information that was collected before to your written notice. You will be given a signed copy of this form. This consent form does not have an expiration date.

WHO DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?

If you have further questions about the study, please call 773-834-0555.

If you have any questions about your rights in this research study you may contact the IRB, which protects participants in research projects. You may reach the Committee office between 8:30 am and 5:00 pm, Monday through Friday, by calling (773) 702-6505 or by writing: University of Chicago, Institutional Review Board, 5841 S. Maryland Ave., MC7132, I-625, Chicago, IL 60637.

Consent

I have received information about this research project and the procedures. No guarantee has been given about possible results. I will receive a signed copy of this consent form for my records.

I give my permission to participate in the above research project.

Signature of Subject:

Date:

I give my permission for my child/relative/the person I represent to participate in the above research project.

Signature of Parent / Legal Guardian / Legally Authorized Representative:

Date: